Announcements Trials
Browse Landscape

Status

Unknown 2Enrolling by invitation 1Completed 1

Sponsor Class

OTHER 4

Study Type

Interventional 68Observational 4

Sponsor

Cancer Type

Gastrointestinal 3Other solid neoplasm 1

Conditions

Stomach Neoplasms 1Solid Tumor 1Recurrence 1Rectal Neoplasms 1Gallbladder Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1

Interventions

Surveys and Questionnaires 529Blood Specimen Collection 405Surgical Procedures, Operative 151Interviews as Topic 131Radiotherapy 130Observation 122Drug Therapy 122Magnetic Resonance Spectroscopy 104Biopsy 103Specimen Handling 70Data Collection 70Neoadjuvant Therapy 65Immunohistochemistry 64Magnetic Resonance Imaging 61Immune Checkpoint Inhibitors 58Watchful Waiting 51Immunotherapy 51Bevacizumab 49Positron Emission Tomography Computed Tomography 46Ultrasonography 44Liquid Biopsy 41Hematologic Tests 41Tomography, X-Ray Computed 40Therapeutics 40Radiosurgery 40Colonoscopy 40pembrolizumab 37Hepatectomy 37Gene Expression Profiling 36High-Energy Shock Waves 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Observational × Tegafur × Clear all
NCT04260269 2024-12-12

CardioSwitch

Helsinki University Central Hospital

Enrolling by invitation
200 enrolled
Other solid neoplasm

Solid Tumor

NCT04856761 2022-08-18

A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection

Fudan University

Unknown
160 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence, Cholangiocarcinoma

NCT03001726 2022-05-06

To Observe the Efficacy and Safety by Comparing Chemotherapy(Docetaxel, Oxaliplatin Plus S1 ) Followed With Radical Resection Versus Chemotherapy Alone in Advanced Gastric Cancer With Single Non-curable Factor.

Shanghai Zhongshan Hospital

Unknown
228 enrolled
Gastrointestinal

Stomach Neoplasms

NCT00898846 2016-09-28

Identifying Prognostic Factors in Patients Receiving Tegafur-Uracil for Stage II Colon Cancer That Was Completely Removed By Surgery

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

Completed
1,111 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡